NYSE:SNN (Smith & Nephew plc)
About SNN
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Smith & Nephew plc (NYSE: SNN) Latest News
Investing Articles
Should You Buy Neil Woodford Rejects HSBC Holdings plc, Reckitt Benckiser Group Plc And Smith & Nephew plc?
Investing Articles
3 FTSE 100 Stocks Set To Soar: SSE PLC, Smith & Nephew plc And Burberry Group plc
Investing Articles
AstraZeneca plc vs Smith & Nephew plc vs Indivior PLC: Which Healthcare Stock Should You Buy?
Investing Articles
Is The Reward Worth The Risk With BT Group plc, Admiral Group PLC, Smith & Nephew plc And Associated British Foods plc?
Investing Articles
Why Neil Woodford Has Sold Smith & Nephew Plc But Bought More Centrica Plc And SSE Plc
Investing Articles
Keep An Eye On Smith & Nephew plc & Shire plc Now!
Investing Articles
Don’t Make These Basic Mistakes With BHP Billiton plc, Smith & Nephew plc And Tungsten Corp PLC
Investing Articles
AstraZeneca plc vs Smith & Nephew plc: Which Is The Better Buy?
Investing Articles
Why Now Is A Great Opportunity To Take Profit On Takeover Target Smith & Nephew plc
Investing Articles
Why Smith & Nephew plc Is Attracting Interest From Stryker Corporation
Investing Articles
3 Neil Woodford Plays On Ageing Populations: AstraZeneca plc, Smith & Nephew plc And Capita PLC
Investing Articles
Is It Time To Cash In On Takeover Target Smith & Nephew plc?
1❯